MediWound Ltd. reported unaudited earnings results for fourth quarter and audited earnings results for the year ended December 31, 2015. For the quarter, the company's revenues were $267,000 against $124,000 a year ago. Operating loss was $6,830,000 against $6,586,000 a year ago. Loss from continuing operations was $7,780,000 against $7,094,000 a year ago. Loss for the period was $7,780,000 against $7,094,000 a year ago. Basic and diluted loss per share from continuing operations was $0.36 against $0.33 a year ago. Basic and diluted loss per share was $0.36 against $0.33 a year ago. Net cash flows used in operating activities was $4,887,000 against $4,381,000 a year ago. Purchase of property and equipment was $78,000. Purchase of intangible assets was $30,000 against $30,000 a year ago. Adjusted LBITDA from continuing operations was $5,978,000 against $5,294,000 a year ago. The increase in revenue was primarily due to sales of NexoBrid associated with the MCI in Romania, which were ordered in addition to the Company's donation of product.

For the year, the company's revenues were $601,000 against $259,000 a year ago. Operating loss was $21,227,000 against $21,427,000 a year ago. Loss from continuing operations was $21,671,000 against $18,875,000 a year ago. Loss for the period was $22,088,000 against $18,875,000 a year ago. Basic and diluted loss per share from continuing operations was $1.00 against $0.95 a year ago. Basic and diluted loss per share was $1.02 against $0.95 a year ago. Net cash flows used in operating activities was $19,601,000 against $16,493,000 a year ago. Purchase of property and equipment was $376,000 against $366,000 a year ago. Purchase of intangible assets was $30,000 against $30,000 a year ago. Adjusted LBITDA from continuing operations was $18,065,000 against $16,108,000 a year ago. The increase in net loss was primarily due to one-time net financial income recognized in 2014, which was largely comprised of non-cash revaluation of warrants.